A mid-level health manager intervention to promote uptake of isoniazid preventive therapy among people with HIV in Uganda: a cluster randomised trial

Elijah Kakande, Canice Christian, Laura B Balzer, Asiphas Owaraganise, Joshua R Nugent, William DiIeso, Derek Rast, Jane Kabami, Jason Johnson Peretz, Carol S Camlin, Starley B Shade, Elvin H Geng, Dalsone Kwarisiima, Moses R Kamya, Diane V Havlir, Gabriel Chamie, Elijah Kakande, Canice Christian, Laura B Balzer, Asiphas Owaraganise, Joshua R Nugent, William DiIeso, Derek Rast, Jane Kabami, Jason Johnson Peretz, Carol S Camlin, Starley B Shade, Elvin H Geng, Dalsone Kwarisiima, Moses R Kamya, Diane V Havlir, Gabriel Chamie

Abstract

Background: Despite longstanding guidelines endorsing isoniazid preventive therapy (IPT) for people with HIV, uptake is low across sub-Saharan Africa. Mid-level health managers oversee IPT programmes nationally; interventions aimed at this group have not been tested. We aimed to establish whether providing structured leadership and management training and facilitating subregional collaboration and routine data feedback to mid-level managers could increase IPT initiation among people with HIV compared with standard practice.

Methods: We conducted a cluster randomised trial in Uganda among district-level health managers. We randomly assigned clusters of between four and seven managers in a 1:1 ratio to intervention or control groups. Our intervention convened managers into mini-collaboratives facilitated by Ugandan experts in tuberculosis and HIV, and provided business leadership and management training, SMS platform access, and data feedback. The control was standard practice. Participants were not masked to trial group, but study statisticians were masked until trial completion. The primary outcome was IPT initiation rates among adults with HIV in facilities overseen by participants over a period of 2 years (2019-21). We conducted prespecified analyses that excluded the third quarter of 2019 (Q3-2019) to understand intervention effects independent of a national 100-day IPT push tied to a financial contingency during Q3-2019. This trial is registered with ClinicalTrials.gov (NCT03315962), and is ongoing.

Findings: Between Nov 15, 2017, and March 14, 2018, managers from 82 of 82 eligible districts (61% of Uganda's 135 districts) were enrolled and randomised: 43 districts to intervention, 39 to control. Intervention delivery took place between Dec 6, 2017, and Feb 2, 2022. Over 2 years, IPT initiation rates were 0·74 versus 0·65 starts per person-year in intervention versus control groups (incidence rate ratio [IRR] 1·14, 95% CI 0·88-1·46; p=0·16). Excluding Q3-2019, IPT initiation was higher in the intervention group versus the control group: 0·32 versus 0·25 starts per person-year (IRR 1·27, 95% CI 1·00-1·61; p=0·026).

Interpretation: Following an intervention targeting managers in more than 60% of Uganda's districts, IPT initiation rates were not significantly higher in intervention than control groups. After accounting for large increases in IPT from a 100-day push in both groups, the intervention led to significantly increased IPT rates, sustained after the push and during the COVID-19 pandemic. Our findings suggest that interventions centred on mid-level health managers can improve IPT implementation on a large, subnational scale, and merit further exploration to address key public health challenges for which strong evidence exists but implementation remains suboptimal.

Funding: National Institute of Allergy and Infectious Diseases.

Conflict of interest statement

Declaration of interests We declare no competing interests.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1:. Trial profile
Figure 1:. Trial profile
*Two managers (one district health officer and one tuberculosis supervisor) per district. In one district, one manager (district health officer) declined to participate, but this manager’s district was represented by the tuberculosis supervisor. †Three districts were divided, creating three new districts. ‡One district was divided, creating one new district. §One district was excluded due to lack of data for primary and secondary outcomes.
Figure 2:. IPT initiation incidence rates over…
Figure 2:. IPT initiation incidence rates over time in intervention versus control groups
IPT=isoniazid preventive therapy. MoH=Ministry of Health.

References

    1. Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid prophylactic therapy for the prevention of tuberculosis in HIV infected adults: a systematic review and meta-analysis of randomized trials. PLoS One 2015; 10: e0142290.
    1. Ross JM, Badje A, Rangaka MX, et al. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV 2021; 8: e8–15.
    1. WHO. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
    1. Getahun H, Granich R, Sculier D, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS 2010; 24 (suppl 5): S57–65.
    1. WHO. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization, 2011.
    1. van Halsema CL, Fielding KL, Chihota VN, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010; 24: 1051–55.
    1. Swaminathan S, Menon PA, Gopalan N, et al. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One 2012; 7: e47400.
    1. WHO. WHO consolidated guidelines on tuberculosis. Module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
    1. UNAIDS. Confronting inequalities: lessons for pandemic responses from 40 years of AIDS. Geneva: Joint United Nations Programme on HIV/AIDS, 2021.
    1. Kiggundu J Uganda 100-day TPT scale up. Uganda, Ministry of Health (MOH)—AIDS Control Program. Nov 13, 2019. (accessed Oct 11, 2021).
    1. Green L, Kreuter M. Health promotion planning: an educational and environmental approach. Palo Alto, CA: Mayfield Publishers, 1991.
    1. Institute for Healthcare Improvement. The Breakthrough Series: IHI’s collaborative model for achieving breakthrough improvement. IHI Innovation Series white paper. Boston, MA: Institute for Healthcare Improvement, 2003.
    1. Uzzi B, Amaral L, Reed-Tsochas F. Small-world networks and management science research: a review. Eur Manag Rev 2007; 4: 77–91.
    1. Wood W Attitude change: persuasion and social influence. Annu Rev Psychol 2000; 51: 539–70.
    1. Kotter JP. Leading change. Boston: Harvard Business School Press, 1996.
    1. Panchadsaram R What is an OKR? Definition and examples. (accessed Oct 1, 2021).
    1. Beck C, D’Elia P, Lamond MW. Easy and effective professional development: the power of peer observation to improve teaching. New York, NY: Routledge, 2014.
    1. Uganda Ministry of Health. Isoniazid preventive therapy in Uganda: a health worker’s guide. (accessed March 29, 2022).
    1. Hayes RJ, Moulton LH. Cluster randomized trials. New York, NY: Chapman and Hall, 2009.
    1. van der Laan M, Rose S. Targeted learning: causal inference for observational and experimental data. New York, NY: Springer Science+Business Media, 2011.
    1. Balzer LB, van der Laan MJ, Petersen ML, SEARCH Collaboration. Adaptive pre-specification in randomized trials with and without pair-matching. Stat Med 2016; 35: 4528–45.
    1. Watkins DC. Rapid and rigorous qualitative data analysis: the “RADaR” technique for applied research. Int J Qual Methods 2017; 16: 1–9.
    1. Orkin AM, Gill PJ, Ghersi D, et al. Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement. JAMA 2021; 326: 257–65.
    1. Uganda Ministry of Health. 100-day accelerated isoniazid preventive therapy scale up plan, version 1.0. June, 2019. (accessed Oct 7, 2021).
    1. PEPFAR. PEPFAR Uganda Country Operational Plan (COP) 2019 strategic direction summary. April 12, 2019. (accessed Oct 7, 2021).
    1. Charles MK, Lindegren ML, Wester CW, et al. Implementation of tuberculosis intensive case finding, isoniazid preventive therapy, and infection control (“Three I’s”) and HIV-tuberculosis service integration in lower income countries. PLoS One 2016; 11: e0153243.
    1. Melgar M, Nichols C, Cavanaugh JS, et al. Tuberculosis preventive treatment scale-up among antiretroviral therapy patients—16 countries supported by the U.S. President’s Emergency Plan for AIDS Relief, 2017–2019. MMWR Morb Mortal Wkly Rep 2020; 69: 329–34.
    1. WHO. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
    1. Johnson O, Begg K, Kelly AH, Sevdalis N. Interventions to strengthen the leadership capabilities of health professionals in Sub-Saharan Africa: a scoping review. Health Policy Plan 2021; 36: 117–33.
    1. Desta BF, Abitew A, Beshir IA, Argaw MD, Abdlkader S. Leadership, governance and management for improving district capacity and performance: the case of USAID transform: primary health care. BMC Fam Pract 2020; 21: 252.
    1. Heerdegen ACS, Aikins M, Amon S, Agyemang SA, Wyss K. Managerial capacity among district health managers and its association with district performance: a comparative descriptive study of six districts in the Eastern Region of Ghana. PLoS One 2020; 15: e0227974.
    1. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012; 6: CD000259.
    1. Gengiah S, Barker PM, Yende-Zuma N, et al. A cluster-randomized controlled trial to improve the quality of integrated HIV-tuberculosis services in primary healthcare clinics in South Africa. J Int AIDS Soc 2021; 24: e25803.

Source: PubMed

3
購読する